Articles related to CONTROLLED MEDICINES

Understanding the distinction between probable cause for arrest and evidence required for conviction is crucial for prescribers managing controlled substances.

Rapid symptom improvement and sustained 4-week benefits distinguish Spravato monotherapy in treatment-resistant depression, with significant MADRS score reductions versus placebo.

The expansion of this recall highlights the critical importance of verifying medication packaging against blister strip labeling, particularly for controlled substances where precise dosing is essential.

The FDA’s recent warning about compounded ketamine products underscores the need for rigorous clinical studies to investigate ketamine’s benefit-risk profile and safe-use conditions in the treatment of psychiatric disorders.

Despite the potential benefits of ketamine in treating a range of neurological and psychiatric disorders, the FDA has issued warnings about the potential risks associated with its use, emphasizing the need for careful prescription and clinical oversight.

The DEA and HHS have extended telehealth prescribing flexibilities through December 31, 2024. This critical service allows for continued prescribing of controlled medications via virtual practice, addressing a significant need for many patients with mental health conditions and substance use disorders.